Extracellular vesicles derived from fetal stem cells in early pregnancy modulate glycolysis and lipid metabolism to induce apoptosis in cancer cells.

Authors

Jangho Lee, Kyoungshik Cho, Songrae Kim, Eunsil Cho, Hyejin Kook, Suman Kang, Junho Kim, Mi Hyeon Cho, Sanghee Nah, Seung Hae Kwon, Jin-Chul Kim, Hoibin Jeong

Published in

Translational oncology. Volume 72. Pages 102938. Jul 27, 2026. Epub Jul 27, 2026.

Abstract

Glycolytic dependency in solid tumors underlies resistance to current therapies. We developed antitumoral fetal stem cell-derived extracellular vesicles (itAT-FSC-EVs) using an ex vivo multistage conditioning workflow to enhance their metabolism-modulating capacity and evaluated their effects in cellular and animal models. In colorectal (HCT116) and hepatic (HepG2) cancer cells, itAT-FSC-EVs reduced lactate release and downregulated pyruvate dehydrogenase kinase 1, indicating pyruvate influx into mitochondria. This was accompanied by reduced glycolytic activity, increased oxygen consumption, and elevated mitochondrial membrane potential. Reactive oxygen species accumulated and contributed to cytotoxicity, culminating in apoptosis, whereas normal HEK293 cells remained viable with transient oxidative stress. Cancer cells exhibited suppression of lipogenic genes, including fatty acid synthase, reduced mitochondrial mass and a sustained increase in the NADP/NADPH ratio, indicating impaired redox buffering despite enhanced respiration. In HCT116 xenografts, systemic itAT-FSC-EV administration reduced tumor growth and lowered pyruvate dehydrogenase kinase 1 and fatty acid synthase levels, supporting a metabolic reset in vivo. These findings indicate that itAT-FSC-EVs reprogram malignant cells from glycolytic dependence toward mitochondrial oxidative metabolism, disrupt redox homeostasis, and induce cell death. This approach may synergistically modulate the tumor niche with immunotherapy by lowering lactate production, an immunosuppressive factor in solid tumors. Thus, itAT-FSC-EVs represent a metabolism-rewiring biological system with translational potential for normalizing tumor metabolism and complementing existing anticancer modalities.

PMID:
42508145
Bibliographic data and abstract were imported from PubMed on 28 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.